Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.

MLA

McGregor, Bradley, et al. “Health-Related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.” European Urology, vol. 81, no. 5, May 2022, pp. 515–22. EBSCOhost, https://doi.org/10.1016/j.eururo.2022.01.032.

APA

McGregor, B., O’Donnell, P. H., Balar, A., Petrylak, D., Rosenberg, J., Yu, E. Y., Quinn, D. I., Heath, E. I., Campbell, M., Hepp, Z., McKay, C., Steinberg, J., Regnault, A., Mazerolle, F., & Galsky, M. D. (2022). Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. European Urology, 81(5), 515–522. https://doi.org/10.1016/j.eururo.2022.01.032

Chicago

McGregor, Bradley, Peter H. O’Donnell, Arjun Balar, Daniel Petrylak, Jonathan Rosenberg, Evan Y. Yu, David I. Quinn, et al. 2022. “Health-Related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.” European Urology 81 (5): 515–22. doi:10.1016/j.eururo.2022.01.032.